Frank Porreca

Affiliations: 
University of Arizona, Tucson, AZ 
Area:
pain, opioids, pharmacology
Google:
"Frank Porreca"
Mean distance: 16.78 (cluster 32)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Yakhnitsa V, Ji G, Hein M, et al. (2022) Kappa Opioid Receptor Blockade in the Amygdala Mitigates Pain Like-Behaviors by Inhibiting Corticotropin Releasing Factor Neurons in a Rat Model of Functional Pain. Frontiers in Pharmacology. 13: 903978
Sato D, Narita M, Hamada Y, et al. (2022) Relief of neuropathic pain by cell-specific manipulation of nucleus accumbens dopamine D1- and D2-receptor-expressing neurons. Molecular Brain. 15: 10
Martin L, Ibrahim M, Gomez K, et al. (2021) Conotoxin contulakin-G engages a neurotensin receptor 2 /R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception. Pain
Lançon K, Qu C, Navratilova E, et al. (2021) Decreased dopaminergic inhibition of pyramidal neurons in anterior cingulate cortex maintains chronic neuropathic pain. Cell Reports. 37: 109933
Mehr-Un-Nisa, Munawar MA, Rankin D, et al. (2021) C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters. Bioorganic & Medicinal Chemistry. 51: 116509
Bharadwaj VN, Porreca F, Cowan RP, et al. (2021) A new hypothesis linking oxytocin to menstrual migraine. Headache
Lee YS, Remesic M, Ramos-Colon C, et al. (2021) Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism. Biomedicines. 9
Phelps CE, Navratilova E, Porreca F. (2021) Cognition in the Chronic Pain Experience: Preclinical Insights. Trends in Cognitive Sciences
Hein M, Ji G, Tidwell D, et al. (2021) Kappa opioid receptor activation in the amygdala disinhibits CRF neurons to generate pain-like behaviors. Neuropharmacology. 185: 108456
Kopruszinski CM, Thornton P, Arnold J, et al. (2020) Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia : An International Journal of Headache. 333102420966581
See more...